Food Effect Clinical Trial
Official title:
An Open-Label, 2-Way, 2-Period Crossover Study of Orally Administered VS-6766 in Healthy Adult Subjects to Determine the Effect of Food on the Pharmacokinetics of VS-6766
Verified date | May 2022 |
Source | Verastem, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An Open-Label, 2-Way, 2-Period Crossover Study of Orally Administered VS-6766 in Healthy Adult Subjects to Determine the Effect of Food on the Pharmacokinetics of VS-6766
Status | Completed |
Enrollment | 18 |
Est. completion date | April 12, 2022 |
Est. primary completion date | April 12, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Healthy, adult, male or female (of non-childbearing potential only), 18-55 years of age, inclusive, at the screening visit. 2. Must follow protocol specified contraception guidance. 3. Continuous non-smoker who has not used tobacco/nicotine-containing products for at least 3 months prior to the first dosing based on subject self-reporting. 4. Body mass index (BMI) = 18.0 and = 32.0 kg/m2 at the screening visit. 5. Medically healthy with no clinically significant medical history. 6. Able to swallow capsules. 7. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol. Exclusion Criteria: 1. Presence of systemic or severe infection. 2. History or presence of a significant medical condition or disease which is not completely resolved. 3. History or presence of alcohol or drug abuse 4. History or presence of hypersensitivity or reaction to the study drug or related compounds. 5. History of tuberculosis. 6. Presence of any fever within 2 weeks prior to first dosing. 7. Females able to have children. 8. Females who are pregnant or lactating. 9. Presence of HIV. 10. Must be able to refrain from using any drugs, including prescription and non-prescription medications beginning 28 days prior to the first dosing. 11. Lactose Intolerance. 12. Donation of blood or significant blood loss or blood transfusion within 56 days prior to the first dosing. 13. Plasma donation within 7 days prior to the first dosing. 14. Participation in another clinical study within 30 days prior to the first dosing. |
Country | Name | City | State |
---|---|---|---|
United States | Celerion | Tempe | Arizona |
Lead Sponsor | Collaborator |
---|---|
Verastem, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: AUC0-t | Area under plasma Concentration (AUC) 0 to t | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: AUC0-120 | Area under plasma Concentration (AUC) from 0-120 minutes | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: AUC0-inf | Area under plasma Concentration (AUC) from zero to infinity | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: AUC%extrap | Area under plasma Concentration (AUC) extrapolated | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: Cmax | Cmax for VS-6766 administered with and without food. | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: Tlag | absorption lag-time (Tlag) | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: Tmax | time of Maximum concentration (Tmax) | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: Kel | Elimination rate (Kel) | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: T1/2 | concentration Half-life (T1/2) | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: CL/F | Oral Clearance (CL/F) | 30 days | |
Primary | Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: Vz/F | Apparent Volume of Distribution (Vz/F) for VS-6766 administered with and without food. | 30 days | |
Secondary | To assess the safety and tolerability of a single-dose of VS-6766 administered with or without a standardized high-fat/high-calorie meal in healthy adult subjects. | Treatment emergent adverse events/ treatment emergent serious adverse events - their frequency, duration and severity, lab parameters, vital signs, ECG and ophthalmologic changes | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04501640 -
A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants
|
Phase 4 | |
Completed |
NCT01224587 -
Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions
|
Phase 1 | |
Withdrawn |
NCT02560363 -
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT02017236 -
A Food Effect Phase I Study of the Volitinib in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03150498 -
A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001
|
Phase 1 | |
Completed |
NCT01686217 -
A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K
|
Phase 1 | |
Completed |
NCT01322464 -
Study to Assess Food Effect on Sativex Bioavailability
|
Phase 1 | |
Completed |
NCT03885778 -
A Food Effect Study of Besifovir in Healthy Subjects
|
Phase 4 | |
Completed |
NCT05690932 -
A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05217732 -
Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers
|
Phase 1 |